LadRx (CYTR) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Lord Abbett Developing Growth R3 (LADRX)October 17, 2024 | ca.finance.yahoo.comLord Abbett Developing Growth R3September 19, 2024 | morningstar.comLord Abbett Developing Growth Fund;R3September 17, 2024 | wsj.comLadRx Corporation (LADX) Latest Stock News & Headlines - Yahoo FinanceAugust 25, 2024 | finance.yahoo.comNasdaq Korea Consumer Staples Index (NQKR45:IND) Stock Price, Quote, News & Analysis - Seeking AlphaJuly 19, 2024 | seekingalpha.comLadRx Corporation (LADX)May 17, 2024 | finance.yahoo.comLadRx Corporation (LADX) Stock Historical Prices & Data - Yahoo FinanceAugust 11, 2023 | finance.yahoo.comLadRx Corporation Issues Corporate Update for 3Q22November 27, 2022 | finance.yahoo.comLadRx Corporation Announces OTCQB Ticker Change to LADX - Business WireOctober 5, 2022 | businesswire.comCYTRX CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comSeptember 23, 2022 | marketscreener.comCytRx Corporation Relaunches as LadRx Corporation - Business WireSeptember 23, 2022 | businesswire.comEuropean Patent Office Awards CytRx Key Patent - Business WireSeptember 7, 2022 | businesswire.comADIAL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.comAugust 25, 2022 | marketscreener.comCYTR.PK - CytRx Corporation | Stock Price & Latest News | ReutersAugust 21, 2022 | reuters.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Business WireAugust 9, 2022 | businesswire.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of DirectorsAugust 9, 2022 | finance.yahoo.comCYTRX CORP : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.comJuly 27, 2022 | marketscreener.com2022-05-19 | OTCQB:CYTR | Press Release | CytRx Corporation - StockhouseMay 20, 2022 | stockhouse.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Business WireMay 20, 2022 | businesswire.comCYTRX CORP : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comMay 20, 2022 | marketscreener.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Yahoo FinanceMay 19, 2022 | finance.yahoo.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Marketscreener.comMay 19, 2022 | marketscreener.comCytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.May 17, 2022 | finance.yahoo.comArcellx (ACLX) Appoints Olivia Ware to its Board - StreetInsider.comMay 16, 2022 | streetinsider.comCytRx Partners with Oncology Development Expert to Advance LADR Platform - Business WireApril 20, 2022 | businesswire.comCytRx Partners with Oncology Development Expert to Advance LADR PlatformApril 20, 2022 | finance.yahoo.comGene Therapies & Associated Vectors 2022: Intellectual Property Landscape, Patent Valuation Analysis, Granted Patents and Claims Analysis - PR NewswireApril 13, 2022 | prnewswire.comForm 424B3 CYTRX CORP - StreetInsider.comMarch 25, 2022 | streetinsider.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Benzinga - BenzingaMarch 23, 2022 | benzinga.comCYTRX CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comMarch 23, 2022 | marketscreener.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Yahoo FinanceMarch 21, 2022 | finance.yahoo.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate ProgressMarch 21, 2022 | finance.yahoo.comOrphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce By Benzinga - Investing.com UKMarch 12, 2022 | uk.investing.comOrphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce - Benzinga - BenzingaMarch 11, 2022 | benzinga.comCytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates - Business WireMarch 10, 2022 | businesswire.comCytRx to absorb subsidiary Centurion BioPharma; former CEO retires from boardMarch 9, 2022 | seekingalpha.comCytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates - Yahoo FinanceMarch 9, 2022 | finance.yahoo.comInvestor Presentation: February 2022 - marketscreener.comFebruary 26, 2022 | marketscreener.comHealth Care Sector Update for 02/24/2022: ORPH,CYTR,FEMY,CLRB,EVH,LNTH - NasdaqFebruary 24, 2022 | nasdaq.comCytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type CFebruary 24, 2022 | finance.yahoo.comCytRx : FAQ on Issuance of Shares to Armistice Capital and Special Meeting of Shareholders to Approve Increase in Authorized Shares - Form 8-K - marketscreener.comFebruary 17, 2022 | marketscreener.comCytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C - Business WireFebruary 14, 2022 | businesswire.comCytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type CFebruary 14, 2022 | finance.yahoo.comOrphazyme gains on plans to resubmit U.S. marketing application for arimoclomol - Seeking AlphaFebruary 11, 2022 | seekingalpha.comCYTRX CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - marketscreener.comJanuary 26, 2022 | marketscreener.comCytRx : Shareholder Letter, mailed on January 25, 2022 (furnished herewith pursuant to Item 7.01) - Form 8-K - marketscreener.comJanuary 26, 2022 | marketscreener.comCytRx to Hold Town Hall for Stockholders on Thursday, January 20thJanuary 18, 2022 | finance.yahoo.comCytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference - marketscreener.comJanuary 7, 2022 | marketscreener.comOculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China) - Yahoo Finance UKJanuary 5, 2022 | uk.finance.yahoo.comCytRx : Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer - Form 8-K - marketscreener.comJanuary 4, 2022 | marketscreener.com Get LadRx News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter. Email Address 917 Trades… Zero Losses? (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.” Go here to see how you can start accessing these opportunities today CYTR Media Mentions By Week CYTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTR News Sentiment▼0.000.49▲Average Medical News Sentiment CYTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTR Articles This Week▼00▲CYTR Articles Average Week Get LadRx News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IKT News INAB News AIM News NKGN News TSBX News SNTI News PHGE News EVAX News COEP News BCLI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYTR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LadRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
